Not medical advice. Tirzepatide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Tirzepatide combines GLP-1 and GIP activity in one molecule; papers highlight dual incretin mechanisms and metabolic endpoints in controlled studies.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Tirzepatide, dual GIP/GLP-1 receptor agonist with imbalanced agonism favouring GIP, with body-composition reductions reported in published research.
Peer-reviewed literature typically discusses Tirzepatide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 2.5–15 mg subcutaneously (dose escalation) · Once weekly subcutaneous injection · t½ ≈ 5 days (116.7 h mean); Tmax = 8–72 h; Vd ≈ 10.3 L; 99% albumin bound; bioavailability ~80%; dose escalation: 2.5 mg × 4 wk → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Metabolized via proteolytic cleavage, C20 diacid β-oxidation, and amide hydrolysis; ~66% renal / ~33% fecal elimination as metabolites.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Tirzepatide is a dual GIP and GLP-1 receptor agonist (a "twincretin") — the peptide best known as the active ingredient in Eli Lilly's Mounjaro and Zepbound. Tirzepatide is the research-grade form of this tirzepatide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is NOT Mounjaro or Zepbound, is not an approved medicine, and is not for human use.
In the published literature tirzepatide activates both the GIP and GLP-1 receptors, combining their satiety, insulin-secretion and adipose-tissue effects — which is why it is described as a "dual incretin" agonist. These are mechanisms reported for the molecule in research, not human-use guidance; Tirzepatide is supplied for laboratory research only.
Not exactly — tirzepatide is a DUAL agonist: it activates both the GIP receptor and the GLP-1 receptor, whereas semaglutide activates GLP-1 alone. That second (GIP) arm is the key structural difference. Tirzepatide is the research-grade tirzepatide peptide, supplied for research use only.
It is the same active peptide (tirzepatide) but NOT the same product. Mounjaro and Zepbound are FDA-approved, prescription, sterile finished pharmaceuticals made under cGMP. Tirzepatide is an unapproved, research-grade lyophilised powder sold for laboratory research only — not for human consumption and not a substitute for any prescribed medication.
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors. The added GIP receptor activity drives additional satiety and adipose-tissue effects, producing larger weight loss and HbA1c reductions in published research.
It is a full agonist at GIPR (comparable potency to native GIP) but biased at GLP-1R, favouring cAMP signalling over β-arrestin recruitment. The asymmetry preserves the GIP arm while reducing the receptor desensitisation that can blunt long-term efficacy at GLP-1R.
Keep the lyophilised powder at −20 °C in the freezer. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Avoid repeated freeze-thaw cycles, which can damage the fatty acid tail and reduce potency.
Published trials of the reference drug (the SURMOUNT-4 withdrawal study of tirzepatide) report that stopping a GIP/GLP-1 receptor agonist leads to a return of appetite and substantial regain of lost weight over the following months, as the dual receptor stimulation that suppressed appetite and slowed gastric emptying ends. Those findings describe the approved medicine in human studies — Tirzepatide is an unapproved research-grade peptide for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside Tirzepatide.
Primary literature and registries for Tirzepatide, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: GIP/GLP-1 Dual Agonist, Dual Incretin Agonist, Twincretin